ECSP034444A - Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina - Google Patents

Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina

Info

Publication number
ECSP034444A
ECSP034444A EC2003004444A ECSP034444A ECSP034444A EC SP034444 A ECSP034444 A EC SP034444A EC 2003004444 A EC2003004444 A EC 2003004444A EC SP034444 A ECSP034444 A EC SP034444A EC SP034444 A ECSP034444 A EC SP034444A
Authority
EC
Ecuador
Prior art keywords
derivatives
pyrimidine
pirrolo
phenyl
amino
Prior art date
Application number
EC2003004444A
Other languages
English (en)
Inventor
Guido Bold
Giorgio Caravatti
Hans-Georg Capraro
Peter Traxler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034444A publication Critical patent/ECSP034444A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención se refiere a derivados de 7H-pirrolo (2,3-d) pirimidina de la fórmula I en donde los símbolos y sustituyentes son como se definen en la descripción, a procesos para su preparación, a composiciones farmacéuticas que comprenden estos derivados, y al uso de estos derivados - solos o en combinación con uno o más compuestos farmacéuticos activos deferentes - para la preparación de composiciones farmacéuticas para el tratamiento en especial de una enfermedad proliferativa, tal como un tumor.
EC2003004444A 2001-08-07 2003-01-21 Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina ECSP034444A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119249.1A GB0119249D0 (en) 2001-08-07 2001-08-07 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP034444A true ECSP034444A (es) 2004-08-27

Family

ID=9919959

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004444A ECSP034444A (es) 2001-08-07 2003-01-21 Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina

Country Status (32)

Country Link
US (2) US7244729B2 (es)
EP (1) EP1416935B8 (es)
JP (1) JP4147184B2 (es)
KR (1) KR100597505B1 (es)
CN (2) CN1538847A (es)
AR (1) AR036213A1 (es)
AT (1) ATE388713T1 (es)
AU (1) AU2002324029B2 (es)
BR (1) BR0211801A (es)
CA (1) CA2453881C (es)
CY (1) CY1108129T1 (es)
DE (1) DE60225563T2 (es)
DK (1) DK1416935T3 (es)
EC (1) ECSP034444A (es)
ES (1) ES2302830T3 (es)
GB (1) GB0119249D0 (es)
HK (1) HK1065483A1 (es)
HU (1) HUP0401083A3 (es)
IL (2) IL159832A0 (es)
MX (1) MXPA04001191A (es)
MY (1) MY140398A (es)
NO (1) NO328791B1 (es)
NZ (1) NZ530824A (es)
PE (1) PE20030349A1 (es)
PL (1) PL365783A1 (es)
PT (1) PT1416935E (es)
RU (1) RU2318826C2 (es)
SG (1) SG156521A1 (es)
SI (1) SI1416935T1 (es)
TW (1) TWI324159B (es)
WO (1) WO2003013541A1 (es)
ZA (1) ZA200400271B (es)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200711A (et) * 2000-06-26 2004-06-15 Pfizer Products Inc. Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
AU2002340139A1 (en) * 2001-10-09 2003-04-22 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
ES2388138T3 (es) 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
BRPI0416909A (pt) * 2003-11-25 2007-01-16 Pfizer Prod Inc método de tratamento de aterosclerose
AR047470A1 (es) * 2004-01-29 2006-01-18 Novartis Ag Derivados de pirrolo-pirimidina utiles para el tratamiento de enfermedades proliferativas,composiciones farmaceuticas que los contienen,y procesos para su preparacion
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
EP1731523A4 (en) * 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINE DERIVATIVE
DK2253614T3 (da) 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
AU2005250285B2 (en) 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP5096142B2 (ja) * 2004-07-30 2012-12-12 メチルジーン インコーポレイテッド Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
DK1827437T3 (da) * 2004-12-15 2012-02-13 Sigma Tau Ind Farmaceuti Kombinationer af terapeutiske midler til cancerbehandling
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US20080227980A1 (en) * 2005-08-05 2008-09-18 Novartis Ag Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative
CA2629245C (en) 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
AU2007206925A1 (en) * 2006-01-23 2007-07-26 Novartis Ag Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
JP2009532497A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
EP2606890A1 (en) 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
CN101443002B (zh) 2006-05-09 2012-03-21 诺瓦提斯公司 包含铁螯合剂和抗肿瘤药的组合及其用途
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
NZ576234A (en) * 2006-11-06 2011-06-30 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CN101626758A (zh) 2007-02-15 2010-01-13 诺瓦提斯公司 用于治疗癌症的lbh589和其他治疗剂的组合
JP5298128B2 (ja) * 2007-08-08 2013-09-25 グラクソスミスクライン エルエルシー 癌の治療用のＩＧＦ−１Ｒ阻害剤としての２−［（２−｛フェニルアミノ｝−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）アミノ］ベンズアミド誘導体
MX2010010525A (es) 2008-03-24 2010-10-25 Novartis Ag Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
EP2260020B1 (en) 2008-03-26 2014-07-23 Novartis AG Hydroxamate-based inhibitors of deacetylases b
JP4884570B2 (ja) * 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
AU2010279188A1 (en) * 2009-07-28 2012-02-23 Ube Industries, Ltd. Pyrrolo[2,3-d]pyrimidine derivative
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
IN2012DN01693A (es) 2009-08-26 2015-06-05 Novartis Ag
BR112012010519A2 (pt) 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
EA201200823A1 (ru) 2009-12-08 2013-02-28 Новартис Аг Гетероциклические производные сульфонамидов
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
JP2014500308A (ja) 2010-12-21 2014-01-09 ノバルティス アーゲー Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
EP2723740A1 (en) 2011-06-27 2014-04-30 Novartis AG Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
CN103732596B (zh) * 2011-07-08 2016-06-01 诺华股份有限公司 吡咯并嘧啶衍生物
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
AP4055A (en) 2011-12-22 2017-03-07 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859876A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859869A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015308A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
JP6427097B2 (ja) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌を処置するための組成物および該組成物を製造するための方法
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
WO2014048869A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
WO2014048894A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN105431204A (zh) 2013-07-12 2016-03-23 奥普索特克公司 用于治疗或预防眼科病的方法
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015042078A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2015148714A1 (en) 2014-03-25 2015-10-01 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
US9399637B2 (en) 2014-03-28 2016-07-26 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2015241198A1 (en) 2014-04-03 2016-11-17 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3194572B1 (en) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Media for culturing pluripotent stem cells
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US20190119284A1 (en) * 2016-04-19 2019-04-25 The Regents Of The University Of California ErbB Inhibitors and Uses Thereof
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
AU2017382406A1 (en) 2016-12-23 2019-04-18 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
KR20200112900A (ko) 2018-01-20 2020-10-05 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 아미노피리미딘 화합물 및 이의 사용 방법
WO2020023628A1 (en) 2018-07-24 2020-01-30 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
CN113874015A (zh) 2018-12-21 2021-12-31 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
EP4192509A1 (en) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
US11814388B1 (en) 2020-08-28 2023-11-14 Ferris State University Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers
GB2617409A (en) 2022-04-27 2023-10-11 Cancertain Ltd Method for predicting responsiveness to therapy
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5877178A (en) * 1991-04-08 1999-03-02 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
EP0682027B1 (de) * 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
JPH09218320A (ja) * 1996-02-14 1997-08-19 Fujitsu Ltd 光海底中継器
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
JP4242928B2 (ja) * 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト 置換ピロロピリミジンおよびその製造方法
AU7210398A (en) 1997-03-27 1998-10-22 Novartis Ag Intermediate products and method for the production of pyrimidine derivatives
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
ID26698A (id) 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
HUP0204272A3 (en) 2000-01-18 2005-03-29 Pfizer Prod Inc Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.

Also Published As

Publication number Publication date
PE20030349A1 (es) 2003-05-29
RU2004106783A (ru) 2005-07-27
US7244729B2 (en) 2007-07-17
MXPA04001191A (es) 2005-02-17
IL159832A0 (en) 2004-06-20
GB0119249D0 (en) 2001-10-03
ES2302830T3 (es) 2008-08-01
US20070161632A1 (en) 2007-07-12
WO2003013541A1 (en) 2003-02-20
CY1108129T1 (el) 2014-02-12
HUP0401083A2 (hu) 2004-09-28
AR036213A1 (es) 2004-08-18
AU2002324029B2 (en) 2005-01-27
NO20040540L (no) 2004-02-05
DK1416935T3 (da) 2008-07-07
US7390805B2 (en) 2008-06-24
CA2453881C (en) 2010-09-28
RU2318826C2 (ru) 2008-03-10
TWI324159B (en) 2010-05-01
PL365783A1 (en) 2005-01-10
EP1416935A1 (en) 2004-05-12
US20040242600A1 (en) 2004-12-02
EP1416935B8 (en) 2008-08-27
CN1538847A (zh) 2004-10-20
NZ530824A (en) 2005-08-26
CA2453881A1 (en) 2003-02-20
BR0211801A (pt) 2004-08-31
SI1416935T1 (sl) 2008-08-31
MY140398A (en) 2009-12-31
ATE388713T1 (de) 2008-03-15
NO328791B1 (no) 2010-05-18
CN101560214B (zh) 2011-05-25
PT1416935E (pt) 2008-06-18
ZA200400271B (en) 2004-11-01
CN101560214A (zh) 2009-10-21
KR20040023730A (ko) 2004-03-18
IL159832A (en) 2012-09-24
EP1416935B1 (en) 2008-03-12
JP2005501077A (ja) 2005-01-13
JP4147184B2 (ja) 2008-09-10
HUP0401083A3 (en) 2007-12-28
HK1065483A1 (en) 2005-02-25
KR100597505B1 (ko) 2006-07-10
SG156521A1 (en) 2009-11-26
DE60225563D1 (de) 2008-04-24
WO2003013541A8 (en) 2004-02-26
DE60225563T2 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
AR028948A1 (es) Compuestos novedosos
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
PA8551001A1 (es) Nuevos compuestos
UY27446A1 (es) Nuevos compuestos
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP055525A (es) Inhibidores de cinasas de tirosina
UY28623A1 (es) Derivados de pirazol y usos de los mismos
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PA8680701A1 (es) Derivados de oxindol
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
PA8432901A1 (es) Compuestos de piridilpirrol
DE60314623D1 (de) Substituierte pyrazolopyrimidine
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
ATE300541T1 (de) Pyrazolopyridinderivate
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.